Black Diamond Therapeutics, Inc.
BDTX Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$1.69
KIRA · Stoqly’s AI analyst, in plain words
- Black Diamond Therapeutics, Inc. had $70.0M of revenue in fiscal 2025.
- Its operating margin was 17.9%: of every 100 in sales, about 18 is left after running the business.
- Black Diamond Therapeutics, Inc. made $22.4M of net profit in fiscal 2025.
Market cap
$97.0M
P/E
—
Revenue
$70.0M
Net income
$22.4M
Free cash flow
—
Operating margin
17.9%
Black Diamond Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
32.0%
Yes. It keeps 32.0% of every sale as profit.
How healthy are the accounts?
6 / 7
Mixed. It passes 6 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Black Diamond Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 16, 2026
- Legal name
- Black Diamond Therapeutics, Inc.
- CIK
- 0001701541
Black Diamond Therapeutics, Inc. · BDTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | — | $0.0M | $70.0M |
| Operating margin | — | — | — | — | 17.9% |
| Net income | −$126M | −$91.2M | −$82.4M | −$69.7M | $22.4M |
| Net margin | — | — | — | — | 32.0% |
| Diluted EPS | −$3.47 | −$2.52 | −$1.88 | −$1.27 | $0.39 |
| Cash | |||||
| Cash from operations | −$100M | −$85.1M | −$66.7M | −$62.3M | $29.6M |
| Capital expenditure | $2.7M | $0.2M | $0.0M | $0.0M | — |
| Free cash flow | −$103M | −$85.3M | −$66.8M | −$62.3M | — |
| Share count change | 10.0% | 0.4% | 21.0% | 25.2% | 4.6% |
| Debt and strength | |||||
| Cash and short-term investments | $210M | $123M | $131M | $98.6M | $129M |
| Shareholders' equity | $196M | $116M | $117M | $83.3M | $112M |
| Current ratio | 9.1x | 8.4x | 6.8x | 4.9x | 8.4x |
| Returns and quality | |||||
| Return on equity | −49.9% | −58.5% | −70.9% | −69.7% | 22.9% |
| Return on tangible equity | −64.1% | −78.8% | −70.6% | −83.7% | 19.9% |
| Piotroski F-score | — | — | — | — | 6 |
| Altman Z'' | 2.4 | −3.3 | −4.6 | −10.7 | −0.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Black Diamond Therapeutics, Inc. · BDTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.69 a share, the company is worth $97.0M.
Source: SEC EDGAR XBRL filings (CIK 0001701541). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.